What is the story about?
What's Happening?
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has awarded nearly $2 million in G-Rex Grants to eight California cell and gene therapy facilities. These grants are part of the California Institute for Regenerative Medicine (CIRM) Manufacturing Network initiative, which aims to enhance operations and establish partnerships to position California as a leading hub for cell and gene therapy manufacturing. The grants, ranging from $125,000 to $300,000, support various projects, including the development of novel virus-like particles and CAR-T cell therapies. Recipients include prestigious institutions such as UC San Diego, City of Hope, Stanford Medicine, USC/CHLA, UC Davis, UCSF, UCLA, and Cedars Sinai.
Why It's Important?
The awarding of these grants underscores California's pivotal role in advancing cell and gene therapy manufacturing. By supporting academic GMP facilities, the initiative aims to foster innovation and streamline the development of cost-effective therapies. This could significantly impact the biotechnology industry, potentially accelerating the availability of new treatments for patients. The collaboration between academic institutions and industry partners may also lead to breakthroughs in therapeutic approaches, enhancing the state's reputation as a leader in regenerative medicine.
What's Next?
The grant recipients will continue to develop and refine their manufacturing processes, with some therapies already entering clinical trials. ScaleReady has also introduced a free program to promote efficient CGT manufacturing, partnering with Hanson Wade to launch the LEAN Cell & Gene event series. This initiative invites CGT entities to learn strategies for improving operations and product quality. The ongoing support and collaboration may lead to further advancements in cell and gene therapy, potentially influencing global practices.
AI Generated Content
Do you find this article useful?
